Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Study Overview
=================
Brief Summary
-----------------
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart failure (CHF) (cohort 2).

Detailed Description
-----------------
This was a non-interventional, retrospective cohort study using secondary data sources from the Optum Clinformatics® Data Mart (CDM) and 100% files of the CMS Medicare RIFs. Two study cohorts were constructed to include adult Heart Failure with reduced ejection fraction (HFrEF) patients who newly initiated sacubitril/valsartan (Cohort 1) and adult Chronic Heart Failure (CHF) patients who newly initiated sacubitril/valsartan (Cohort 2). The date of first prescription fill for sacubitril/valsartan during the cohort identification period was defined as index date. A 12-month washout period was employed to ascertain the new user status. The Healthcare Resource Utilization (HCRU) and costs of care outcomes will be measured within both the 12 months post-index period and the 12 months pre-index period.

Official Title
-----------------
A Pre-post Analysis of Healthcare Resource Utilization and Costs of Care in a New User Cohort of Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Drug: sacubitril/valsartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cohort 1 - Adult HFrEF patients Newly initiated sacubitril/valsartan during the cohort identification period; Presence of an International Classification of Diseases, Tenth revision (ICD-10) diagnosis code for systolic HF (I50.1x, I50.2x, I50.4x) on one inpatient hospital claim or two outpatient medical claims during the cohort identification period; That are ≥ 18 years old at index date; That are treated with sacubitril/valsartan continuously for a minimum of 90-days following treatment initiation; That are continuously enrolled in medical and prescription pharmacy benefits in both the pre-index and post-index period, with any gap in coverage of <45 days allowed. Cohort 2 - Adult CHF patients Newly initiated sacubitril/valsartan during the cohort identification period; Presence of ICD-10 diagnosis code for systolic HF or diastolic HF (I50.1x, I50.2x, I50.3x, I50.4x) on one inpatient hospital claim or two outpatient medical claims during the cohort identification period; That are ≥ 18 years old at index date; That are treated with sacubitril/valsartan continuously for a minimum of 90-days following treatment initiation; That are continuously enrolled in medical and prescription pharmacy benefits in both the pre-index and post-index period, with any gap in coverage of <45 days allowed. Exclusion Criteria: - Patients who died during the post-index period will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1 - Adult HFrEF patients<br>adult HFrEF patients who newly initiated sacubitril/valsartan | Drug: sacubitril/valsartan<br>* Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).<br>|
| Cohort 2 - Adult CHF patients<br>adult CHF patients who newly initiated sacubitril/valsartan | Drug: sacubitril/valsartan<br>* Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean number of Heart Failure - specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Number of Heart Failure (HF)-specific hospitalizations was defined as the number of acute inpatient hospitalizations with a primary discharge diagnosis of HF. An acute inpatient hospitalization was defined as a medical claim for an inpatient hospitalization. | Baseline, 12 months post initiation of sacubitril/valsartan | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean number of HF - related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Number of HF-related hospitalizations was defined as the number of acute inpatient hospitalizations with a discharge diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean number of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Number of all-cause hospitalizations was as the number of acute inpatient hospitalizations for any reason. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean number of Urgent Heart Failure (UHF) visits of adult HFrEF patients treated with sacubitril/valsartan | An UHF visit was defined as any of the following: i) a patient with a place of service (POS) code 20, which corresponds to urgent care facility ii) a patient with an ER visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0450, 0451, 0452, 0456 or 0459 iii) a patient with an urgent care clinic visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0516 or 0526 iv) a patient with a hospital observational stay (POS code = 22, 23), identified from revenue code 0762 | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean number of Worsening Heart Failure (WHF) episodes of adult HFrEF patients treated with sacubitril/valsartan | Number of WHF episodes was defined as a composite outcome of HF-specific hospitalizations and UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean costs of HF-specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of HF-specific hospitalizations was defined as the sum of payer paid amounts for acute inpatient hospitalizations with a primary discharge diagnosis of HF. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean costs of HF-related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of HF-related hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations with a discharge diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean costs of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan | Costs of all-cause hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations for any reason. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean costs of UHF visits of adult HFrEF patients treated with sacubitril/valsartan | Costs of UHF visits were defined as the sum of payer paid amounts for UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean costs of WHF episodes of adult HFrEF patients treated with sacubitril/valsartan | Costs of WHF episodes were defined as the sum of payer paid amounts for HF-specific hospitalizations and UHF visits. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean HF-specific costs of adult HFrEF patients treated with sacubitril/valsartan | HF-related costs were defined as the sum of payer paid amounts for medical claims with a diagnosis of HF in any position. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean all-cause medical costs of adult HFrEF patients treated with sacubitril/valsartan | All-cause medical costs were defined as the sum of payer paid amounts for all medical claims. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean all-cause pharmacy costs of adult HFrEF patients treated with sacubitril/valsartan | All-cause pharmacy costs were defined as the sum of payer paid amounts for all pharmacy claims. | Baseline, 12 months post initiation of sacubitril/valsartan | 
| Mean all-cause total cost of care of adult HFrEF patients treated with sacubitril/valsartan | All-cause total cost of care were defined as the sum of all-cause medical costs and all-cause pharmacy costs. | Baseline, 12 months post initiation of sacubitril/valsartan | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure,, Medicare Advantage,, Commercial,, HFrEF,, Chronic heart failure